Table 2.
Characterization of recurrent genetic mutations according to the recommendation by ELN, 2022
| Risk group | Mutations |
|---|---|
| Favourable | ·Mutated NPM1 |
| ·bZIP in-frame mutated CEBPA | |
| Intermediate | ·Mutated NPM1 with FLT3-ITD |
| ·Wild-type NPM1 with FLT3-ITD (without adverse-risk genetic lesions) | |
| ·Cytogenetic and/or molecular abnormalities not classified as favorable or adverse | |
| Adverse | ·Mutated ASXL1, BCOR, EZH2, RUNX1, SF3B1, SRSF2, STAG2, U2AF1, and/or ZRSR2 (in absence of favourable risk subtype) |
| ·Mutated TP53 |